Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 761-767

  Calvo, E ^a   Malik, S N ^b   Siu, L L ^c   Baillargeon, G M ^b   Irish, J ^c   Chin, S F ^c   Santabarbara, P ^d   Kreisberg, J I ^b   Rowinsky, Eric K ^a,b,e   Hidalgo, M ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d OSI PHARMACEUTICALS INC   (United States)

^e ImClone Systems   (United States)

Author keywords

EGFR; Erlotinib; Head and neck cancer; Pharmacodynamics; Translational

Indexed keywords

DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; OSI 420; PROTEIN KINASE B; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STEADY STATE; TUMOR BIOPSY; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN;

EID: 34047190928     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl495     Document Type: Article

References (25)

1. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: Emerging treatment improvement strategies. Head Neck 2003; 25: 152-167.
2. Akita RW, Sliwkowski MX. Preclinical studies with erlotinib (tarceva). Semin Oncol 2003; 30: 15-24.
3. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 2003; 30: 23-31.
4. Herbst RS. Erlotinib (tarceva): An update on the clinical trial program. Semin Oncol 2003; 30: 34-46.
5. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353: 123-132.
6. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848.
7. Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748.
8. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
9. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
10. Malik SN, Siu LL, Rowinsky EK et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9: 2478-2486.
11. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-1987.
12. Daneshmand M, Parolin DA, Hirte HW et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003; 9: 2457-2464.
13. Hidalgo A, Tabernero J, Rojo F et al. Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs. Abdom Imaging 2005; 30: 65-68.
14. Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22: 204.
15. Clark GM, Perez-Soler R, Siu LL et al. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 2003; 22: 196.
16. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
17. Rojo F, Tabernero J, Van Cutsem E et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 2003; 22: 191.
18. Tan AR, Yang X, Hewitt SM et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22: 3080-3090.
19. Tabernero J, Rojo F, Jimenez E et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22: 191.
20. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-1176.
21. Vanhoefer U, Tewes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-184.
22. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825.
23. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
24. Busse D, Doughty RS, Ramsey TT et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 2000; 275: 6987-6995.
25. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3: 2703-2707.